These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37587841)

  • 1. Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management.
    O'Connor L; Carbone S; Gobbo A; Gamble H; Faraone SV
    Expert Rev Clin Pharmacol; 2023; 16(9):799-812. PubMed ID: 37587841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
    May DE; Kratochvil CJ
    Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder.
    Heal DJ; Gosden J; Smith SL
    Adv Pharmacol; 2024; 99():251-286. PubMed ID: 38467483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viloxazine extended-release capsules for the treatment of attention-deficit/ hyperactivity disorder in adult patients.
    Childress A; Sottile R; Khanbijian S
    Expert Rev Neurother; 2023; 23(11):945-953. PubMed ID: 37846759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants.
    Childress A
    Expert Opin Pharmacother; 2024 May; 25(7):853-866. PubMed ID: 38771653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating serdexmethylphenidate and dexmethylphenidate capsules as a once-daily treatment option for ADHD.
    Barnhardt EA; Narayanan AR; Coury DL
    Expert Opin Pharmacother; 2023; 24(11):1215-1219. PubMed ID: 37226489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Post Hoc Comparison of Prior ADHD Medication Dose and Optimized Delayed-release and Extended-release Methylphenidate Dose in a Pivotal Phase III Trial.
    Childress AC; Uchida CL; Po MD; DeSousa NJ; Incledon B
    Clin Ther; 2020 Dec; 42(12):2332-2340. PubMed ID: 33168234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of amphetamine extended release once-daily options for the management of attention-deficit hyperactivity disorder.
    Abbas K; Barnhardt EW; Nash PL; Streng M; Coury DL
    Expert Rev Neurother; 2024 Apr; 24(4):421-432. PubMed ID: 38391788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are all ADHD medications created equal? Exploring the differences that enable evening dosing.
    Mattingly GW; Carbray JA; Roy P; López FA
    Postgrad Med; 2024 Jun; 136(5):475-486. PubMed ID: 38904469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An updated safety review of the current drugs for managing ADHD in children.
    Ryst E; Childress A
    Expert Opin Drug Saf; 2023; 22(11):1025-1040. PubMed ID: 37843488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADHD medication use, adherence, persistence and cost among Texas Medicaid children.
    Barner JC; Khoza S; Oladapo A
    Curr Med Res Opin; 2011; 27 Suppl 2():13-22. PubMed ID: 21973228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges.
    López FA; Leroux JR
    Atten Defic Hyperact Disord; 2013 Sep; 5(3):249-65. PubMed ID: 23564273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Supervised off-label prescribing of methylphenidate in adult ADHD].
    Carton L; Dondaine T; Deheul S; Marquié C; Brigadeau F; Amad A; Devos D; Danel T; Bordet R; Cottencin O; Gautier S; Ménard O
    Encephale; 2019 Feb; 45(1):74-81. PubMed ID: 30122296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
    Childress A; Hoo-Cardiel A; Lang P
    Expert Opin Pharmacother; 2020 Mar; 21(4):417-426. PubMed ID: 31971448
    [No Abstract]   [Full Text] [Related]  

  • 18. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options.
    Hodgkins P; Shaw M; Coghill D; Hechtman L
    Eur Child Adolesc Psychiatry; 2012 Sep; 21(9):477-92. PubMed ID: 22763750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.
    Katzman MA; Sternat T
    CNS Drugs; 2014 Nov; 28(11):1005-33. PubMed ID: 25120227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
    Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
    CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.